NCT00042341 2022-05-27
Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)
Sanofi
Phase 2 Completed
Clinical Trials
8 trialsNCT02544789 2015-09-09
Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia
Betta Pharmaceuticals Co., Ltd.
Phase 2 Completed
NCT00991133 2015-04-30
A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)
Sanofi
Phase 1 Completed
NCT00315705 2014-04-14
A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.
Sanofi
Phase 1/2 Completed
NCT01196013 2014-03-19
A Study of Clofarabine in Japanese Paediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukaemia
Sanofi
Phase 1 Completed
NCT00930098 2014-02-11
A Phase II, Open-Label Study of Clofarabine in Paediatric Patients With Refractory/Relapsed Acute Lymphoblastic Leukaemia
Sanofi
Phase 2 Completed
NCT00125840 2014-02-05
Clofarabine in Adult Patients With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT01500161 2013-11-25
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Texas Oncology Cancer Center
Phase 2 Terminated